Skip to main content
Top

21-07-2016 | Endocrine cancers | Book chapter | Article

11. Surgical Management of Sporadic Medullary Thyroid Cancer (Extent of Thyroid Resection and the Role of Central and Lateral Neck Dissection)

Authors: Randall P. Scheri, Sanziana A. Roman, Julie Ann Sosa

Publisher: Springer International Publishing

Abstract

Sporadic medullary thyroid cancer (MTC) encompasses approximately 70–75 % of patients diagnosed with MTC. The American Thyroid Association (ATA) published revised guidelines for the management of MTC in 2015. In their 66 recommendations, surgery remains the mainstay of treatment for sporadic MTC; lymph node metastases are frequent and occur even with early-stage primary tumors, arguing for aggressive compartment-oriented lymph node dissections in patients without suspected distant metastases. Administration of vandetanib or cabozantinib is indicated for patients with progressive MTC that is locally advanced and unresectable, or associated with progressive distant metastases not amenable to surgical excision. Optimally, patients with MTC should be referred to high-volume endocrine centers with experienced multidisciplinary teams and high-volume thyroid surgeons in order to enhance patient outcomes and facilitate enrollment in MTC clinical databases and clinical trials studying novel treatments of metastatic MTC.
Literature
1.
Veiga LH, Neta G, Aschebrook-Kilfoy B, Ron E, Devesa SS. Thyroid cancer incidence patterns in Sao Paulo, Brazil, and the U.S. SEER program, 1997–2008. Thyroid. 2013;23(6):748–57.CrossRefPubMedPubMedCentral
2.
Leboulleux S, Baudin E, Travagli JP, Schlumberger M. Medullary thyroid carcinoma. Clin Endocrinol (Oxf). 2004;61(3):299–310.CrossRef
3.
Roman S, Lin R, Sosa JA. Prognosis of medullary thyroid carcinoma: demographic, clinical, and pathologic predictors of survival in 1252 cases. Cancer. 2006;107(9):2134–42.CrossRefPubMed
4.
Kebebew E, Ituarte PH, Siperstein AE, Duh QY, Clark OH. Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and a comparison of staging systems. Cancer. 2000;88(5):1139–48.CrossRefPubMed
5.
Moley JF, DeBenedetti MK. Patterns of nodal metastases in palpable medullary thyroid carcinoma: recommendations for extent of node dissection. Ann Surg. 1999;229(6):880–7 (discussion 7–8).CrossRefPubMedPubMedCentral
6.
Moley JF. Medullary thyroid carcinoma: management of lymph node metastases. J Natl Compr Canc Netw. 2010;8(5):549–56.PubMed
7.
Elisei R, Bottici V, Luchetti F, Di Coscio G, Romei C, Grasso L, et al. Impact of routine measurement of serum calcitonin on the diagnosis and outcome of medullary thyroid cancer: experience in 10,864 patients with nodular thyroid disorders. J Clin Endocrinol Metab. 2004;89(1):163–8.CrossRefPubMed
8.
Wells SA Jr, Asa SL, Dralle H, Elisei R, Evans DB, Gagel RF, et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid. 2015;25(6):567–610.CrossRefPubMedPubMedCentral
9.
Elisei R, Romei C, Cosci B, Agate L, Bottici V, Molinaro E, et al. RET genetic screening in patients with medullary thyroid cancer and their relatives: experience with 807 individuals at one center. J Clin Endocrinol Metab. 2007;92(12):4725–9.CrossRefPubMed
10.
Eng C, Mulligan LM, Smith DP, Healey CS, Frilling A, Raue F, et al. Low frequency of germline mutations in the RET proto-oncogene in patients with apparently sporadic medullary thyroid carcinoma. Clin Endocrinol (Oxf). 1995;43(1):123–7.CrossRef
11.
Hasselgren M, Hegedus L, Godballe C, Bonnema SJ. Benefit of measuring basal serum calcitonin to detect medullary thyroid carcinoma in a Danish population with a high prevalence of thyroid nodules. Head Neck. 2010;32(5):612–8.PubMed
12.
Machens A, Ukkat J, Hauptmann S, Dralle H. Abnormal carcinoembryonic antigen levels and medullary thyroid cancer progression: a multivariate analysis. Arch Surg. 2007;142(3):289–93 (discussion 94).CrossRefPubMed
13.
Wells SA Jr, Haagensen DE Jr, Linehan WM, Farrell RE, Dilley WG. The detection of elevated plasma levels of carcinoembryonic antigen in patients with suspected or established medullary thyroid carcinoma. Cancer. 1978;42(3 Suppl):1498–503.CrossRefPubMed
14.
Wang TS, Ocal IT, Sosa JA, Cox H, Roman S. Medullary thyroid carcinoma without marked elevation of calcitonin: a diagnostic and surveillance dilemma. Thyroid. 2008;18(8):889–94.CrossRefPubMed
15.
Fugazzola L, Pinchera A, Luchetti F, Iacconi P, Miccoli P, Romei C, et al. Disappearance rate of serum calcitonin after total thyroidectomy for medullary thyroid carcinoma. Int J Biol Markers. 1994;9(1):21–4.PubMed
16.
Suzuki H. Calcitonin levels in normal individuals with new highly sensitive chemiluminescent enzyme immunoassay. J Clin Lab Anal. 1998;12(4):218–22.CrossRefPubMed
17.
Basuyau JP, Mallet E, Leroy M, Brunelle P. Reference intervals for serum calcitonin in men, women, and children. Clin Chem. 2004;50(10):1828–30.CrossRefPubMed
18.
Wells SA Jr, Franz C. Medullary carcinoma of the thyroid gland. World J Surg. 2000;24(8):952–6.CrossRefPubMed
19.
Engelbach M, Gorges R, Forst T, Pfutzner A, Dawood R, Heerdt S, et al. Improved diagnostic methods in the follow-up of medullary thyroid carcinoma by highly specific calcitonin measurements. J Clin Endocrinol Metab. 2000;85(5):1890–4.PubMed
20.
Brandi ML, Gagel RF, Angeli A, Bilezikian JP, Beck-Peccoz P, Bordi C, et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab. 2001;86(12):5658–71.CrossRefPubMed
21.
Trimboli P, Treglia G, Guidobaldi L, Romanelli F, Nigri G, Valabrega S, et al. Detection rate of FNA cytology in medullary thyroid carcinoma: a meta-analysis. Clin Endocrinol (Oxf). 2015;82(2):280–5.CrossRef
22.
Trimboli P, Cremonini N, Ceriani L, Saggiorato E, Guidobaldi L, Romanelli F, et al. Calcitonin measurement in aspiration needle washout fluids has higher sensitivity than cytology in detecting medullary thyroid cancer: a retrospective multicentre study. Clin Endocrinol (Oxf). 2014;80(1):135–40.CrossRef
23.
Giraudet AL, Vanel D, Leboulleux S, Auperin A, Dromain C, Chami L, et al. Imaging medullary thyroid carcinoma with persistent elevated calcitonin levels. J Clin Endocrinol Metab. 2007;92(11):4185–90.CrossRefPubMed
24.
Costante G, Meringolo D, Durante C, Bianchi D, Nocera M, Tumino S, et al. Predictive value of serum calcitonin levels for preoperative diagnosis of medullary thyroid carcinoma in a cohort of 5817 consecutive patients with thyroid nodules. J Clin Endocrinol Metab. 2007;92(2):450–5.CrossRefPubMed
25.
Iacobone M, Niccoli-Sire P, Sebag F, De Micco C, Henry JF. Can sporadic medullary thyroid carcinoma be biochemically predicted? Prospective analysis of 66 operated patients with elevated serum calcitonin levels. World J Surg. 2002;26(8):886–90.CrossRefPubMed
26.
Karges W, Dralle H, Raue F, Mann K, Reiners C, Grussendorf M, et al. Calcitonin measurement to detect medullary thyroid carcinoma in nodular goiter: German evidence-based consensus recommendation. Exp Clin Endocrinol Diabetes. 2004;112(1):52–8.CrossRefPubMed
27.
Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW, Wiersinga W, et al. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol. 2006;154(6):787–803.CrossRefPubMed
28.
Colombo C, Verga U, Mian C, Ferrero S, Perrino M, Vicentini L, et al. Comparison of calcium and pentagastrin tests for the diagnosis and follow-up of medullary thyroid cancer. J Clin Endocrinol Metab. 2012;97(3):905–13.CrossRefPubMed
29.
Daniels GH. Screening for medullary thyroid carcinoma with serum calcitonin measurements in patients with thyroid nodules in the United States and Canada. Thyroid. 2011;21(11):1199–207.CrossRefPubMed
30.
Cheung K, Roman SA, Wang TS, Walker HD, Sosa JA. Calcitonin measurement in the evaluation of thyroid nodules in the United States: a cost-effectiveness and decision analysis. J Clin Endocrinol Metab. 2008;93(6):2173–80.CrossRefPubMed
31.
American Thyroid Association Guidelines Taskforce on Thyroid N, Differentiated Thyroid C, Cooper DS, Doherty GM, Haugen BR, Kloos RT, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19(11):1167–214.CrossRef
32.
Weber T, Schilling T, Frank-Raue K, Colombo-Benkmann M, Hinz U, Ziegler R, et al. Impact of modified radical neck dissection on biochemical cure in medullary thyroid carcinomas. Surgery. 2001;130(6):1044–9.CrossRefPubMed
33.
Oskam IM, Hoebers F, Balm AJ, van Coevorden F, Bais EM, Hart AM, et al. Neck management in medullary thyroid carcinoma. Eur J Surg Oncol. 2008;34(1):71–6.CrossRefPubMed
34.
Scollo C, Baudin E, Travagli JP, Caillou B, Bellon N, Leboulleux S, et al. Rationale for central and bilateral lymph node dissection in sporadic and hereditary medullary thyroid cancer. J Clin Endocrinol Metab. 2003;88(5):2070–5.CrossRefPubMed
35.
Kazaure HS, Roman SA, Sosa JA. Medullary thyroid microcarcinoma: a population-level analysis of 310 patients. Cancer. 2012;118(3):620–7.CrossRefPubMed
36.
Machens A, Hauptmann S, Dralle H. Prediction of lateral lymph node metastases in medullary thyroid cancer. Br J Surg. 2008;95(5):586–91.CrossRefPubMed
37.
Machens A, Holzhausen HJ, Dralle H. Contralateral cervical and mediastinal lymph node metastasis in medullary thyroid cancer: systemic disease? Surgery. 2006;139(1):28–32.CrossRefPubMed
38.
Machens A, Dralle H. Biomarker-based risk stratification for previously untreated medullary thyroid cancer. J Clin Endocrinol Metab. 2010;95(6):2655–63.CrossRefPubMed
39.
American Thyroid Association Surgery Working G, American Association of Endocrine S, American Academy of O-H, Neck S, American H, Neck S, et al. Consensus statement on the terminology and classification of central neck dissection for thyroid cancer. Thyroid. 2009;19(11):1153–8.CrossRef
40.
Machens A, Dralle H. Benefit-risk balance of reoperation for persistent medullary thyroid cancer. Ann Surg. 2013;257(4):751–7.CrossRefPubMed
41.
Wells SA Jr, Robinson BG, Gagel RF, Dralle H, Fagin JA, Santoro M, et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol. 2012;30(2):134–41.CrossRefPubMed
42.
Elisei R, Schlumberger MJ, Muller SP, Schoffski P, Brose MS, Shah MH, et al. Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol. 2013;31(29):3639–46.CrossRefPubMedPubMedCentral
43.
Machens A, Hauptmann S, Dralle H. Increased risk of lymph node metastasis in multifocal hereditary and sporadic medullary thyroid cancer. World J Surg. 2007;31(10):1960–5.CrossRefPubMed
44.
Kaserer K, Scheuba C, Neuhold N, Weinhausel A, Haas OA, Vierhapper H, et al. Sporadic versus familial medullary thyroid microcarcinoma: a histopathologic study of 50 consecutive patients. Am J Surg Pathol. 2001;25(10):1245–51.CrossRefPubMed
45.
Miyauchi A, Matsuzuka F, Hirai K, Yokozawa T, Kobayashi K, Ito Y, et al. Prospective trial of unilateral surgery for nonhereditary medullary thyroid carcinoma in patients without germline RET mutations. World J Surg. 2002;26(8):1023–8.CrossRefPubMed
46.
Modigliani E, Cohen R, Campos JM, Conte-Devolx B, Maes B, Boneu A, et al. Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients. The GETC Study Group. Groupe d’etude des tumeurs a calcitonine. Clin Endocrinol (Oxf). 1998;48(3):265–73.CrossRef
47.
Beressi N, Campos JM, Beressi JP, Franc B, Niccoli-Sire P, Conte-Devolx B, et al. Sporadic medullary microcarcinoma of the thyroid: a retrospective analysis of eighty cases. Thyroid. 1998;8(11):1039–44.CrossRefPubMed
48.
Pusztaszeri MP, Bongiovanni M, Faquin WC. Update on the cytologic and molecular features of medullary thyroid carcinoma. Advances in Anatomic Pathology. 2014;21(1):26–35.CrossRefPubMed
49.
Peix JL, Braun P, Saadat M, Berger N, El Khazen M, Mancini F. Occult micro medullary thyroid carcinoma: therapeutic strategy and follow-up. World J Surg. 2000;24(11):1373–6.CrossRefPubMed